80495-47-2Acetazolamide EP Impurity F
● In Stock
| Catalogue No.: | VL11007 |
|---|---|
| CAS No.: | 80495-47-2 |
| Mol. Formula: | C8H9N7O6S4 |
| Mol. Weight: | 427.46 g/mol |
Additional information on CAS 80495-47-2
Parent drug
AcetazolamideIUPAC Name
N-[5-[(5-Acetamido-1, 3, 4-thiadiazol-2-yl)sulfonyl]sulfamoyl-1, 3, 4-thiadiazol-2-yl]acetamide triethylamine saltPharmacopoeial Synonyms
Acetazolamide DimerOther Synonyms
Bis[5-(acetylamino)-1,3,4-thiadiazole-2-sulfonyl]amine; N,N’-[Iminobis(sulfonyl-1,3,4-thiadiazole-5,2-diyl)]bisacetamide; Acetamide, N,N’-(iminobis(sulfonyl-1,3,4-thiadiazole-5,2-diyl))bis-; N,N’-(5,5′-((Hydrosulfonylamino)sulfonyl)bis(1,3,4-thiadiazole-5,2-diyl))diacetamideSmile
CC(=O)NC1=NN=C(S1)S(=O)(=O)NS(=O)(=O)C2=NN=C(S2)NC(=O)CInChI
InChI=1S/C8H9N7O6S4/c1-3(16)9-5-11-13-7(22-5)24(18,19)15-25(20,21)8-14-12-6(23-8)10-4(2)17/h15H,1-2H3,(H,9,11,16)(H,10,12,17)Characterization Data (Included)
HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, and Structure Elucidation Report (SER).Additional Characterization Data
QNMR, D2O Exchange, 13C NMR, 13C APT, COSY NMR, NOESY NMR, 15N NMR, HSQC NMR, HMQC NMR, and HMBC NMR. These are available upon request and may be free or subject to additional charges.Description
Acetazolamide EP Impurity F also referred to in pharmacopoeias as
Acetazolamide Dimer, is a meticulously characterized reference standard. It adheres to stringent regulatory guidelines, including those established by USP, EMA, JP, and BP. This product plays a vital role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial manufacturing of Acetazolamide .Furthermore, it is accompanied by a comprehensive Structure Elucidation Report (SER), ensuring its accuracy and reliability across various analytical applications. Acetazolamide EP Impurity F is an impurity of Acetazolamide. It is also chemically known as an Acetazolamide Dimer Impurity. It has anticonvulsant activity and acts by non-competitively inhibiting carbonic anhydrase enzyme in the Brain.
References
Srinivasu, Prabha, et al. “A Validated Stability-Indicating LC Method for Acetazolamide in the Presence of Degradation Products and Its Process-Related Impurities.” Journal of Pharmaceutical and Biomedical Analysis, vol. 52, no. 1, May 2010, pp. 142–48, https://doi.org/10.1016/j.jpba.2009.12.011. Reiss, William G., and Karen S. Oles. “Acetazolamide in the Treatment of Seizures.” Annals of Pharmacotherapy, vol. 30, no. 5, May 1996, pp. 514–19, https://doi.org/10.1177/106002809603000515.Request a Quote
"*" indicates required fields









